OMV/BEV Isolation, Characterization & Drug Loading Development

OMVs are naturally shed by gram-negative bacteria (including common probiotic strains such as Escherichia coli Nissle 1917, Akkermansia muciniphila, and others), while gram-positive bacteria produce membrane vesicles (MVs) through distinct mechanisms. Creative Biolabs can work with a range of bacterial sources depending on your therapeutic target and prior strain development work. If you are starting from a new strain, our microbial isolation and screening services can be scoped in parallel.

The choice depends on your intended downstream application and the purity requirements at each stage. Ultracentrifugation typically offers higher yield but may co-sediment protein aggregates, while SEC provides gentler separation that better preserves surface integrity for functional and drug-loading assays. Where resources allow, we recommend a head-to-head comparison so the protocol selection is driven by your specific bacterial strain and payload, not by default assumptions. Our team will discuss your program priorities and suggest an appropriate comparative scope during project scoping.

Published research has demonstrated successful loading of small molecule drugs, nucleic acids (siRNA, miRNA, plasmid DNA), peptides, and proteins into bacterial vesicles. The optimal loading method depends heavily on payload size, charge, and hydrophilicity. We conduct a payload-specific screening panel that tests candidate methods (passive incubation, electroporation, sonication, pH-gradient, or surface conjugation) and reports encapsulation efficiency and post-loading integrity for each. This removes guesswork from one of the most critical development steps.

Yes. OMVs and BEVs are non-replicating nanoparticles derived from bacterial membranes; they do not contain genetic material sufficient for bacterial replication and are inherently cell-free. As part of our characterization and QC panel, we include sterility checks and confirm the absence of viable bacterial contamination in the final vesicle preparation. This cell-free profile is one of the key rationales for pursuing OMV/BEV platforms as safer alternatives to live biotherapeutic products in certain applications.

Standard functional validation includes in vitro cell uptake (fluorescent labeling and flow cytometry or confocal microscopy), cytotoxicity profiling on relevant cell lines, and application-specific bioactivity assays (e.g., immune activation markers for immunotherapy applications, or target cell viability for drug delivery applications). Assay panels are scoped in discussion with the client based on therapeutic indication and program stage.

Yes. Creative Biolabs offers an integrated suite of upstream services—including microbial isolation and screening, probiotics characterization, and small-scale and lab-scale microbial production—that can be combined with OMV/BEV isolation and development in a coordinated project. Starting from the bacterial source rather than a pre-isolated vesicle preparation gives our team more control over growth conditions that directly influence vesicle yield and quality.